FDA is announcing that Emergent BioSolutions is extending the shelf-life of newly manufactured NARCAN, or naloxone hydrochloride, 4 milligram Nasal Spray products from 3-years to 4-years. “This action was taken at the request of the FDA and is the latest of multiple steps the Agency has recently taken to prevent overdoses and reduce overdose-related deaths by expanding access to naloxone and other overdose reversal agents,” the agency stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EBS:
- Emergent BioSolutions awarded procurement contract valued up to $235.8M
- Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
- Lightning Could Strike Twice for Biotech Penny Stock Chimerix (NASDAQ:CMRX)
- Emergent BioSolutions receives $75M anthrax vaccine contract from BARDA
- Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing